Poster Viewing
Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non–small Cell Lung Cancer

https://doi.org/10.1016/j.ijrobp.2017.06.1695Get rights and content

Cited by (0)

Author Disclosure: M.F. Gensheimer: Research Grant; Varian Medical Systems. J.C. Hong: None. C.N. Chang-Halpenny: None. N. Eclov: None. J. To: None. J.D. Murphy: None. H.A. Wakelee: Research Grant; BMS, Celgene, Clovis, Exelixis, Lilly, Novartis, Pfizer, Pharmacyclics, Roche/Genentech, Xcovery. Consultant; Peregrine. Advisory Board; Gilead, Pfizer. ; International Thymic Malignancies Interest Group. J.W. Neal: Research Grant; Genentech, Merck, Arqule, Exelixis. Honoraria; Clovis, CARET/Physicians Resource Mgmt., Nektar, BI. Q. Le: Research Grant; Amgen. Travel Expenses; BMS. Stock; Aldea. chair of head and neck committee- design clinical trial; RTOG NRG Cooperative group. president elect; American Radium Society. W. Hara: task force member; NCI Metastatic and Recurrent Head & Neck Task Forc. A. Quon: None. P.G. Maxim: None. E.E. Graves: Research Grant; Varian Biosynergy. ; Society of Nuclear Medicine. M.R. Olson: None. M. Diehn: Employee; Kaiser Permanente. Consultant; Roche. Stock; CiberMed. Stock Options; Quanticel Pharmaceuticals. B.W. Loo: Research Grant; RaySearch, Varian Medical Systems Inc. Stock; TibaRay, Inc.. ; American College of Radiology, National Comprehensive Cancer Network, TibaRay, Inc..

View Abstract